Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon[®] (TARPEYO[®] (budesonide) delayed release capsules/Kinpeygo[®]) in adults with Primary IgA nephropathy (IgAN). The Phase 3 trial met the primary endpoint, estimated glomerular filtration rate (eGFR), with Nefecon demonstrating significant kidney protective effect over placebo.“IgAN is a severe debilitating disease leading to end-stage kidney disease in more than 50% of the patients. The full results from